These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24375768)

  • 1. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
    Guedj J; Yu J; Levi M; Li B; Kern S; Naoumov NV; Perelson AS
    Hepatology; 2014 May; 59(5):1706-14. PubMed ID: 24375768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
    Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
    Buti M; Flisiak R; Kao JH; Chuang WL; Streinu-Cercel A; Tabak F; Calistru P; Goeser T; Rasenack J; Horban A; Davis GL; Alberti A; Mazzella G; Pol S; Orsenigo R; Brass C
    J Viral Hepat; 2015 Jul; 22(7):596-606. PubMed ID: 25412795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.
    Nguyen TH; Mentré F; Levi M; Yu J; Guedj J
    Clin Pharmacol Ther; 2014 Nov; 96(5):599-608. PubMed ID: 25166216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on alisporivir in treatment of viral hepatitis C.
    Flisiak R; Jaroszewicz J; Flisiak I; Łapiński T
    Expert Opin Investig Drugs; 2012 Mar; 21(3):375-82. PubMed ID: 22316207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.
    Dahari H; Shteingart S; Gafanovich I; Cotler SJ; D'Amato M; Pohl RT; Weiss G; Ashkenazi YJ; Tichler T; Goldin E; Lurie Y
    Liver Int; 2015 Feb; 35(2):289-94. PubMed ID: 25251042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
    Ampuero J; Reddy KR; Romero-Gomez M
    World J Gastroenterol; 2016 Jun; 22(22):5285-92. PubMed ID: 27298572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pill for HCV - myth or foreseeable future?
    Jaroszewicz J; Flisiak R; Dusheiko G
    Liver Int; 2014 Jan; 34(1):6-11. PubMed ID: 23998627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
    Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
    Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
    Guedj J; Pang PS; Denning J; Rodriguez-Torres M; Lawitz E; Symonds W; Perelson AS
    Antivir Ther; 2014; 19(2):211-20. PubMed ID: 24464551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the future of ribavirin therapy for hepatitis C?
    Koh C; Liang TJ
    Antiviral Res; 2014 Apr; 104():34-9. PubMed ID: 24468277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of alisporivir for the treatment of hepatitis C infection.
    Stanciu C; Trifan A; Muzica C; Sfarti C
    Expert Opin Pharmacother; 2019 Mar; 20(4):379-384. PubMed ID: 30576256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.
    Layden JE; Layden TJ; Reddy KR; Levy-Drummer RS; Poulakos J; Neumann AU
    J Viral Hepat; 2002 Sep; 9(5):340-5. PubMed ID: 12225328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
    Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
    Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling viral evolutionary dynamics after telaprevir-based treatment.
    Haseltine EL; De Meyer S; Dierynck I; Bartels DJ; Ghys A; Davis A; Zhang EZ; Tigges AM; Spanks J; Picchio G; Kieffer TL; Sullivan JC
    PLoS Comput Biol; 2014 Aug; 10(8):e1003772. PubMed ID: 25101970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.